Nevro Corp. Reports Q2 2024 Earnings: Revenue Down 4.3%
Nevro Corp. Q2 2024 revenue fell 4.3% due to competitive pressures. The company is exploring strategic options for growth.
- Latest
- Trending
Nevro Corp. Q2 2024 revenue fell 4.3% due to competitive pressures. The company is exploring strategic options for growth.
Discover how cutting-edge sports gear and technology are revolutionizing athlete performance at the 2024 Paris Olympics.
The CrowdStrike update mishap and Microsoft outage highlighted the need for cybersecurity preparedness among global leaders.
Rhythm Pharmaceuticals sees robust Q2 2024 results with $29.1M revenues due to IMCIVREE's success in treating Bardet-Biedl syndrome.
Supernus Pharmaceuticals sees a 24% YoY revenue increase in Q2 2024, driven by key drugs Qelbree and GOCOVRI.
The AR and VR market, worth $5.97B in 2023, is set to reach $397.2B by 2031 due to advancements and ...
The AR and VR contact lens market to grow at a 17.2% CAGR from 2024 to 2030, reaching $53.3 million. ...
A hospice center in Yuma introduces VR to offer mobility-limited patients therapeutic benefits and mental relief.
A purported ransomware attack struck the Grand Palais RMN, but quick response minimized impact on affiliated institutions.
Peter Schiff, a gold advocate and crypto skeptic, acknowledges Bitcoin’s real-world applications despite criticizing Bitcoin ETFs.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.